METiS TechBio’s blockbuster IPO signals rising investor interest in AI startups focused on how drugs are delivered inside the body
Updated
May 14, 2026 3:02 PM
HIV-1 virus particles, coloured red. PHOTO: UNSPLASH
Investors are beginning to place bigger bets on AI startups focused on drug delivery infrastructure rather than drug discovery alone. That shift was on display this week after METiS TechBio, a Hong Kong tech-bio startup focused on AI-powered drug delivery systems, debuted on the Hong Kong Stock Exchange.
The listing made METiS TechBio the world’s first publicly traded AI-powered drug delivery startup and the first AI-powered large-molecule biopharmaceutical startup listed in Hong Kong. The startup raised more than HKD 2.1 billion through its IPO, making it the largest healthcare listing in Hong Kong so far in 2026.
Investor demand was unusually strong. The Hong Kong public offering was oversubscribed by more than 6,900 times while the international tranche recorded 82 times oversubscription. More than 280 institutional investors participated in the international placing.
The strong demand reflects a wider shift in AI biotech. Over the past few years, much of the sector’s attention has focused on using AI to discover new drugs or molecules. METiS is taking a different approach. The startup focuses on how medicines are delivered inside the body after they are developed.
That challenge is becoming harder to ignore in biotech. Designing a therapy is only one part of the process. Delivering it precisely to specific organs, tissues or cells remains a major hurdle, especially for newer therapies involving RNA, proteins and large-molecule drugs.
METiS is trying to solve that problem through its proprietary NanoForge platform. The system uses AI to design and test nanodelivery systems that help medicines reach targeted areas inside the body more efficiently. The platform combines AI models, simulation systems and high-throughput screening tools to speed up formulation development and improve delivery precision.
The startup says it has already achieved targeted delivery across eight organs and tissue systems including the liver, lungs, heart, muscles and central nervous system.
One of its lead programs, MTS-004, became China’s first AI-enabled formulation drug to complete a Phase III clinical trial. The drug is being developed for pseudobulbar affect, a neurological condition that affects emotional expression. According to the startup, AI tools helped reduce preclinical formulation development time from up to two years to less than three months.
Investor interest in the IPO also came from some of the world’s largest asset managers and healthcare funds. BlackRock led the cornerstone investments with a USD 50 million subscription. Other participating investors included UBS Asset Management Singapore, Mirae Asset, ORIX Corporation, Deerfield, RTW, Hillhouse Capital and IDG Capital.
METiS is also building what it describes as a “platform collaboration + product partnership” business model. The startup currently works with more than 30 pharmaceutical and biotechnology partners globally, including large pharmaceutical companies and medical research institutions.
The company reported RMB 105 million in revenue in 2025, largely tied to upfront payments connected to its MTS-004 partnership agreements. It also said some platform collaboration contracts could reach milestone values of up to USD 109 million.
Chris Lai said: "The future of biomedicine will no longer be simply about 'taking medicine when one falls ill.' METiS TechBio's ambition is to harness AI to build nano-rockets that can navigate with precision through the inner space of the human body's 30 trillion cells, write the code of nucleic acids and proteins into cells, and reprogram diseased and aging cells into healthy cells. This was our founding aspiration, and it is the mission to which we will dedicate our lives. The IPO marks a new starting point for us to accelerate forward, and we will strive to live up to the support and trust we have received from all sectors."
The IPO also highlights how Hong Kong is increasingly positioning itself as a hub for next-generation biotech and AI healthcare startups. While investor excitement around AI drug discovery has cooled in parts of the market, startups focused on delivery systems and biotech infrastructure are beginning to attract stronger institutional backing.
For METiS, the challenge now will be turning that investor confidence into commercially viable therapies and long-term partnerships. But the listing suggests that AI-driven drug delivery is starting to emerge as a category investors are willing to treat as core biotech infrastructure rather than a niche research experiment.
Keep Reading
Robots enter the World Cup, shifting how large-scale events are run and experienced
Updated
April 20, 2026 1:40 PM
Hyundai Motor Company Dealership, Alabama, US. PHOTO: ADOBE STOCK
As the FIFA World Cup 2026 approaches, attention is beginning to shift beyond the matches themselves to how an event of this scale is organised and run. Managing teams, coordinating venues and handling large crowds requires a system that works with precision. This time, robotics is set to become part of that system.
Hyundai Motor Company, a long-time FIFA partner, is expanding its role for the 2026 tournament. Alongside its traditional responsibility of providing vehicles for teams, officials and media, the company will introduce robotics in collaboration with Boston Dynamics. Robots including Atlas and Spot are expected to be deployed at selected venues.
According to the announcement, these systems will be used to support tournament operations while contributing to safety and efficiency. They will also play a role in shaping how fans experience the event, indicating a broader use of technology within the tournament environment. While specific use cases have not been detailed, the inclusion of robotics reflects a growing effort to integrate advanced systems into large-scale public events.
The direction was introduced through the company’s global campaign, “Next Starts Now,” unveiled at the 2026 New York International Auto Show. The campaign is positioned around its wider focus on innovation across mobility and robotics, aligning with its long-standing partnership with FIFA, which now spans more than two decades. As part of the 2026 tournament, the company will also deploy its largest mobility fleet to date, working alongside these newer systems across venues.
Beyond operations, the initiative extends into community engagement. Youth football camps are set to take place across four host cities in the United States—Atlanta, Miami, New Jersey and Los Angeles—targeting children between the ages of six and twelve. A global drawing programme will also invite young fans to submit artwork supporting their national teams, with selected designs to be featured on official team buses during the tournament.
Taken together, the introduction of robotics alongside existing infrastructure points to a gradual shift in how major events are supported. Rather than operating only behind the scenes, technology is becoming more visible within the event itself. How these systems perform in a live, large-scale setting will become clearer once the tournament begins.